Lincoln Pharma to hold 31st AGM on 30 September 2025, proposes ₹1.80 dividend
The declaration of a dividend directly impacts shareholders' returns. The re-appointment of the Managing Director and other Whole Time Directors ensures leadership stability, which is a significant, though not extraordinary, corporate action.
The company has proposed a dividend of ₹1.80 per share, which is a direct positive return for shareholders. The re-appointment of key managerial personnel and directors indicates stability and continuity in leadership.
* Lincoln Pharmaceuticals Limited will hold its 31st Annual General Meeting (AGM) on Tuesday, 30 September 2025, at 11:00 a.m. (IST) via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). * The agenda includes the adoption of the audited Standalone and Consolidated financial statements for the financial year ended 31 March 2025. * The Board has recommended a dividend of ₹1.80 per equity share (18%) of ₹10 each for the financial year 2024-2025. * The company will seek approval for the re-appointment of Mr. Ashish Rajanikant Patel and Mr. Rajanikant Gulabdas Patel as directors. * Shareholders will vote on the re-appointment of Mr. Mahendra G. Patel as Managing Director for a period of 5 years, effective 01 October 2025. * Re-appointment of Mr. Hashmukh I. Patel as Whole Time Director for 5 years from 01 October 2025, and Mr. Ashish R. Patel and Mr. Munjal M. Patel as Whole Time Directors for 5 years from 14 November 2025 will also be considered. * The AGM will also ratify the remuneration of ₹2,50,000 plus GST for Kiran J. Mehta & Co. as Cost Auditors for FY 2024-2025. * Appointment of M/s. Ankit Sethi & Associates as Secretarial Auditors for 5 years, from FY 2025-26 to FY 2029-30, will be proposed. * The Register of Members and Share Transfer Book will be closed from Saturday, 13 September 2025, to Tuesday, 30 September 2025 (both days inclusive), to determine the list of members entitled to receive the dividend. * The record date for dividend entitlement is 12 September 2025. * Remote e-voting will be available from Friday, 26 September 2025, at 9:00 a.m. (IST) until Monday, 29 September 2025, at 5:00 p.m. (IST).
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.